Microsatellite instability and BRAF and KRAS mutations in stage III colon cancer: Requirements for accurate prognosis assessment
Mené à partir d'échantillons tumoraux prélevés sur 2 559 patients atteints d'un adénocarcinome du côlon de stade III traité par résection puis par chimiothérapie de type FOLFOX4 en combinaison ou non avec le cétuximab (âge médian : 60 ans), cet essai de phase III évalue, en fonction de la stabilité des microsatellites, l'association entre la présence de la mutation V600E du gène BRAF ou de mutations du gène KRAS et la survie sans maladie ou la survie globale des patients
Microsatellite instability (MSI) and mutations of BRAF and KRAS have been investigated as candidate biomarkers of “independent” prognostic value in patients with colorectal cancer for some time.1,2 Depending on tumor stage and treatment, their prognostic value seems to vary, but even in trials with similar populations and treatment the prognostic value is still controversial. Whether and how these 3 biomarkers are associated with outcome in patients with stage III colon cancer treated with combination leucovorin-calcium, fluorouracil, and oxaliplatin (FOLFOX)-based chemotherapy and how they influence each other are relevant research questions.
JAMA Oncology , commentaire, 2015